Japan-based Astellas Pharma Inc. (TSE: 4503) confirmed on Friday the US District Court for the District of Delaware ruling that all asserted claims of the 8,106,183+ADs- 8,524,883+ADs- and RE47301 patents for LEXISCAN(R) (regadenoson injection) 0.4mg/mL are not infringed.
The patent infringement trial involved one Abbreviated New Drug Application (ANDA) filer, US-based pharmaceutical and medical device company Hospira, Inc. According to Astellas, Hospira is requesting permission from the US Food and Drug Administration (FDA) to manufacture and commercialise a generic LEXISCAN(R) product before expiration of the LEXISCAN(R) patents. Astellas said that it plans to appeal the decision and to take legal action to prevent Hospira from launching generic LEXISCAN(R) pending resolution of the appeal.
Astellas said that it is reviewing the potential financial impacts of this district court decision for the fiscal year ending 31 March 2023.
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Krystal Biotech receives FDA approval for updated VYJUVEK label
Renalytix signs collaboration agreement with Tempus AI to expand KidneyIntelX.dkd access
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Implantica produces 10,000 RefluxStop units ahead of planned US launch